

# Regeneron is a global biotechnology company that invents life-transforming medicines for people with serious diseases.

**REGENERON**  
SCIENCE TO MEDICINE®

Founded and led for nearly 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to nine FDA or EMA-approved treatments and numerous product candidates in development, almost all of which were homegrown in the company's laboratories. Regeneron's medicines and investigational pipeline are designed to help patients with blindness-causing eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron has accelerated and improved the traditional drug development process through the proprietary *VelociSuite*® technologies, such as *VelocImmune*®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies for therapeutic use. The company continually pursues ambitious

research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world in the quest for better treatments based on biological insights.

Regeneron has locations in the United States, Canada, the United Kingdom, Ireland, Germany and the Netherlands. It has major product collaborations with global pharmaceutical companies Sanofi, Bayer and Roche. Since 2007, Regeneron and Sanofi have collaborated to discover, develop, manufacture and commercialize human monoclonal antibodies utilizing Regeneron's technologies and scientific expertise. In 2021, Regeneron introduced a new team to support field education for Dupixent® (dupilumab) in several countries outside the U.S., in order to better support patients and complement Sanofi's ongoing commercialization efforts

## General Company Information



- Founded in 1988: Publicly traded company on the NASDAQ exchange (REGN) since 1991
- More than 10,000 employees worldwide, approximately 20% based ex-U.S.; more than 1,000 employees with MD, PhD and/or PharmD degrees
- 9 FDA- or EMA-approved medicines and 30+ investigational medicines in clinical trials
- 2021 revenue of \$16 billion, R&D investment of \$2.9 billion

## Locations



- Tarrytown, NY: Corporate and Research & Development headquarters
- Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations & Product Supply (IOPS) facilities
- Sleepy Hollow, NY, Basking Ridge, NJ and Washington, DC: United States offices
- Amsterdam, Dublin, London, Munich and Toronto: Global business offices

## Leadership Team



- **Leonard S. Schleifer, MD, PhD**  
Founder, President and Chief Executive Officer  
+ Fellow, American Association for the Advancement of Science (AAAS)
- **George D. Yancopoulos, MD, PhD**  
Scientific Founder, President and Chief Scientific Officer  
+ Member, National Academy of Sciences
- **P. Roy Vagelos, MD**  
Chairman of the Board  
+ Former Chief Executive Officer and Chairman of the Board, Merck & Co.  
+ Member, National Academy of Sciences
- **Board of Directors** includes two Nobel Laureates and seven members of the National Academy of Sciences

## Regeneron-Discovered and Approved\* Medicines

**Arcalyst®**  
(rilonacept)  
Injection for Subcutaneous Use

**DUPIXENT®**  
(dupilumab) Injection  
100mg • 200mg • 300mg

**Evkeeza®**  
(evinacumab-dgnb)  
Injection

**EYLEA®**  
(aflibercept) Injection

**Inmazeb™**  
(atoltivimab, maftivimab,  
and odesivimab – ebgm)

**KEVZARA®**  
(sarilumab) injection  
150 mg | 200 mg

**LIBTAYO®**  
(cemiplimab-rwlc)  
Injection 350 mg

**Praluent®**  
(alirocumab) Injection

**ZALTRAP®**  
(ziv-aflibercept)

Dupixent, Libtayo and Kevzara were jointly developed by Regeneron and Sanofi and are marketed in collaboration in the U.S. Dupixent is also marketed in collaboration in certain countries outside of the U.S. Praluent was marketed in collaboration with Sanofi prior to April 2020; effective April 2020, Regeneron is solely responsible for the U.S. development and commercialization, and Sanofi is solely responsible for the ex-U.S. development and commercialization. | Zaltrap is marketed by Sanofi. | Eylea is marketed in collaboration with Bayer outside of U.S. | Arcalyst is marketed by Kiniksa Pharmaceuticals

\* By U.S. Food and Drug Administration and/or European Medicines Agency

REGN.21.06.0004

# Regeneron's Global Footprint

10,000+ employees in 6 countries

Clinical trials in 58 countries



Regeneron-invented medicines available in over 100 countries

## Leaders in Technology

### Fully human monoclonal antibodies

Regeneron has developed a suite of patented technologies known as *VelociSuite*, which includes *VelociGene*®, *VelociImmune*® and *VelociMab*®. These tools allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

### Fusion proteins

Regeneron's novel and patented "Trap" fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

### Regeneron Genetics Center®

The RGC is a large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

### Foster the next generation

Regeneron is driven by science and deeply committed to STEM education that supports the next generation of highly engaged, well-trained and innovative thinkers. Regeneron is the title sponsor of the International Science and Engineering Fair (ISEF), which celebrates the best and brightest young minds from around the globe.

*Fast Company*: Best Workplaces for Innovators, 2021  
*Great Place To Work*: Fortune 100 Best Companies to Work For, 2021  
*Great Place to Work Ireland*: Best Workplaces, 2021  
*Great Place to Work Ireland*: Best Workplaces for Women, 2021  
*Fast Company*: World Changing Ideas (Pandemic Response), 2021  
*IDEA Pharma*: Pharmaceutical Invention Index, 2021  
*Science*: Top Employer, 2021



*Forbes*: JUST Companies, 2021  
Dow Jones Sustainability World Index, 2021  
Dow Jones Sustainability North America Index, 2021  
*Civic 50*: Most Community-Minded Companies in the Nation, 2021  
*Fortune*: Change the World, 2020  
*Shingo Institute*: The Shingo Prize, 2019

To learn more about us, please visit:  
**REGENERON.COM** **@REGENERON**

Regeneron Genetics Center, Science to Medicine, *VelociGene*, *VelociSuite*, *VelociImmune*, *VelociMab*, ARCALYST, EYLEA and LIBTAYO are registered trademarks of Regeneron Pharmaceuticals, Inc. in the U.S.; Praluent and Dupixent are registered trademarks of Sanofi.  
© Regeneron Pharmaceuticals, Inc. 2/22